$-0.01
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-24 Mln
ROE
-10.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.5
Debt to Equity
-0.8
Book Value
$--
EPS
$-1.2
Face value
--
Shares outstanding
54,515,600
CFO
$-97.82 Mln
EBITDA
$-76.42 Mln
Net Profit
$-123.85 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Better Therapeutics Inc (BTTX)
| -- | -- | -- | -99.9 | -97.0 | -- | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Better Therapeutics Inc (BTTX)
| -82.4 | -76.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Better Therapeutics Inc (BTTX)
|
0.0 | 0.0 | 0.0 | -31.6 | -- | -- | -- | 2.3 |
| 0.0 | 0.1 | 0.0 | -12.4 | -65,168.4 | -147.7 | -- | 0.0 | |
| 1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 | |
| 131.8 | 28,613.9 | 0.0 | -1,131.3 | -- | -58.1 | -- | 17.5 |
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform... to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California. Read more
Co-Founder & Executive Chairman
Mr. David P. Perry M.B.A.
Co-Founder & Executive Chairman
Mr. David P. Perry M.B.A.
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Better Therapeutics Inc (BTTX) is $0.00 (NASDAQ) as of 29-Jan-2025 15:00 EDT. Better Therapeutics Inc (BTTX) has given a return of -96.97% in the last 3 years.
Since, TTM earnings of Better Therapeutics Inc (BTTX) is negative, P/E ratio is not available.
The P/B ratio of Better Therapeutics Inc (BTTX) is 2.29 times as on 29-Jan-2025, a 48 discount to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.66
|
-29.19
|
|
2021
|
-2.27
|
2.49
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
-0.66
|
-29.19
|
The 52-week high and low of Better Therapeutics Inc (BTTX) are Rs -- and Rs -- as of 27-Apr-2026.
Better Therapeutics Inc (BTTX) has a market capitalisation of $ 0 Mln as on 29-Jan-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Better Therapeutics Inc (BTTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.